Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04511130
Title Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant
Acronym ARTEMIS
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Marker Therapeutics, Inc.
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.